Retrospective Clinical Research Report

Relationship between serum bilirubin concentration and sarcopenia in patients with type 2 diabetes: a cross-sectional study

Chuan Wang\textsuperscript{1,2,3,4}, Chen Jin\textsuperscript{5}, Xiaofei Yin\textsuperscript{1,2,3,4}, Jidong Liu\textsuperscript{1,2,3,4,*} and Jinbo Liu\textsuperscript{1,2,3,4,*}

Abstract

Objective: The prevalence of sarcopenia is high in patients with type 2 diabetes mellitus (T2DM). Oxidative stress and inflammation play important roles in the pathogenesis of sarcopenia in diabetes. Bilirubin has been shown to possess anti-oxidative activity. We aimed to explore the relationship between bilirubin and sarcopenia in patients with T2DM.

Methods: A total of 251 patients (124 men and 127 postmenopausal women) with T2DM, aged $\geq 50$ years, participated in a cross-sectional study. The serum concentrations of bilirubin (TBIL), direct bilirubin (DBIL) and indirect bilirubin (IBIL) were measured. Muscle mass was measured using dual-energy X-ray absorptiometry.

Results: TBIL and IBIL were positively associated with appendicular skeletal muscle mass index (SMI) in men, but not in women. After adjustment for multiple factors in multiple linear regression analysis, TBIL and IBIL were also significantly associated with SMI in men. In multiple logistic regression analysis, participants in the highest quartile of IBIL demonstrated a lower odds ratio for sarcopenia in men.

Conclusions: Both TBIL and IBIL are positively associated with muscle mass in men with T2DM. Furthermore, IBIL may protect against sarcopenia in men with T2DM.

\textsuperscript{1}Department of Endocrinology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
\textsuperscript{2}Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, China
\textsuperscript{3}Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, China
\textsuperscript{4}Jinan Clinical Research Centre for Endocrine and Metabolic Diseases, Jinan, China
\textsuperscript{5}Department of Endocrinology, Maternity and Child Health Care of Zaozhuang, Zaozhuang, China
\textsuperscript{*}These authors contributed equally to this work.

Corresponding author:
Jinbo Liu, Qilu Hospital of Shandong University, 107 Wenhuixi Road, Jinan 250012, China.
Email: jinboliu@sdu.edu.cn

\textsuperscript{4}Jinan Clinical Research Centre for Endocrine and Metabolic Diseases, Jinan, China
\textsuperscript{5}Department of Endocrinology, Maternity and Child Health Care of Zaozhuang, Zaozhuang, China

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Sarcopenia is characterized by low muscle mass, poor muscle strength and poor physical performance.\(^1\) The prevalence of sarcopenia ranges from 10% to 40% in healthy adults aged \(\geq 60\) years,\(^2\) and patients with sarcopenia are at higher risk of frailty, falls, fracture and even mortality.\(^3,4\) Therefore, screening for risk factors and the development of effective treatments for sarcopenia are extremely important. In 2017, it was estimated that 451 million people worldwide had diabetes and approximately 90% of these people had type 2 diabetes mellitus (T2DM).\(^5\) T2DM increases the risk of sarcopenia,\(^6-9\) but the mechanism whereby this sarcopenia develops remains unclear.

Oxidative stress and inflammation play important roles in the pathogenesis of diabetic sarcopenia.\(^10\) Bilirubin, the end product of haem metabolism, has been recently confirmed to have protective effects in metabolic syndrome and diabetes by antagonizing oxidative stress and chronic inflammation.\(^11-14\) To date, few studies have explored the relationship between bilirubin concentration and sarcopenia and no definitive conclusions have been reached.\(^15,16\) Kawamoto \textit{et al.}\(^15\) found that high serum total bilirubin (TBIL) concentration is associated with higher handgrip strength in community-dwelling Japanese adults. In addition, Kim \textit{et al.}\(^16\) found no association between TBIL and sarcopenia in patients with chronic liver diseases after adjustment for multiple potential confounding factors. However, the relationship between bilirubin concentration and sarcopenia in patients with T2DM has not been characterized. Therefore, we conducted a cross-sectional study to determine whether bilirubin concentration is associated with sarcopenia in middle-aged and elderly patients with T2DM.

Materials and methods

Study participants

Sarcopenia is more common in middle-aged and elderly patients, and most of the inpatients with T2DM in our hospital were \(>50\) years old. Therefore, we performed a cross-sectional study of consecutively recruited patients with T2DM who were aged \(\geq 50\) years at Qilu Hospital, Shandong University, between January 2017 and December 2019. The exclusion criteria were severe liver disease (liver cirrhosis or serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) activities \(>120\) U/L), severe kidney disease (estimated glomerular filtration rate [eGFR] \(<60\) mL/minute/1.73 m\(^2\)), malignant disease, haematological disease and serum bilirubin concentration greater than two times the upper limit of the normal range. Diabetes was diagnosed according to the 2006 World Health Organization criteria:\(^17\) fasting blood glucose (FBG) \(\geq 7.0\) mmol/L and/or a 2-hour postprandial blood glucose concentration \(\geq 11.1\) mmol/L. The study was performed in strict accordance with the provisions of the Declaration of
Helsinki and its amendments, and was approved by the ethics committee of Qilu Hospital of Shandong University (approval no. KYLL-2019-270). All the participants provided their written informed consent.

Data collection

The basic clinical and demographic data for all the participants, including their age, sex, height, body mass, blood pressure (BP) and smoking history, were collected from the computerized patient medical record system of Qilu Hospital of Shandong University. Fasting venous blood samples were collected and immediately used for the measurement of FBG, HbA1c, total cholesterol (TC), triglyceride (TG), ALT, AST, creatinine, TBIL, direct bilirubin (DBIL) and indirect bilirubin (IBIL). Homeostasis model of assessment 2- insulin resistance (HOMA2-IR) was calculated using the FBG and fasting C-peptide concentrations and the formula at http://www.ocdem.ox.ac.uk/. Appendicular skeletal muscle mass (ASM) and body fat percentage were measured using dual-energy X-ray absorptiometry (Discovery Wi, Hologic, Boston, MA, USA). The appendicular skeletal muscle mass index (SMI) was calculated as: SMI (kg/m²) = ASM (kg)/height² (m²). Sarcopenia was defined as a SMI <7.0 kg/m² in men and <5.4 kg/m² in women, according to the Asian Working Group for Sarcopenia recommendations. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.

Statistical analysis

The Kolmogorov–Smirnov test was used to determine whether datasets were normally distributed. Continuous data that were normally distributed or non-normally distributed are expressed as the mean ± standard deviation (SD) and the median (interquartile range), respectively. Student’s t-test (normally distributed data) or Mann–Whitney U-test (non-normally distributed data) were used to compare differences between the two groups. The relationships between serum bilirubin concentration and SMI were assessed using Pearson’s correlation analysis and multiple linear regression analysis in both men and women. Multiple logistic regression analysis was also used to characterize the relationship between the highest quartile of serum bilirubin and sarcopenia. All the statistical analyses were performed using SPSS 23.0 software (IBM Corp., Armonk, NY, USA) and P < 0.05 was considered to represent statistical significance.

Results

General characteristics of the participants

A total of 251 patients (124 men and 127 postmenopausal women) were enrolled. As shown in Table 1, the men with sarcopenia were older and had significantly lower BMI, DBP, fasting C-peptide, HOMA2-IR and TG than those without sarcopenia. Women with sarcopenia were also older and had lower BMI and TC than those without sarcopenia. However, the serum bilirubin (TBIL, DBIL and IBIL) concentrations did not significantly differ between sarcopenic and non-sarcopenic men or women.

Relationships between serum bilirubin and SMI in men and women

To explore the relationship between serum bilirubin concentration and SMI, Pearson’s correlation analyses were performed. As shown in Figure 1, TBIL ($r = 0.211$, $p = 0.019$) and IBIL ($r = 0.249$, $p = 0.005$) positively correlated with SMI in men. However, there were no correlations between serum bilirubin concentrations and SMI in women. We next conducted
Table 1. General characteristics of the study participants, categorized according to sex and the presence of sarcopenia.

| Characteristic           | Men                |       |       |       |       | Women        |       |       |       |       |
|--------------------------|--------------------|-------|-------|-------|-------|--------------|-------|-------|-------|-------|
|                         | Sarcopenia         | Non-sarcopenia | P value | Sarcopenia | Non-sarcopenia | P value |
| N                        | 51                 | 73    |       |       |       | 38           | 89    |       |       |       |
| Age (years)              | 62.61±6.93         | 59.68±5.97 | 0.013 |       |       | 65.32±6.22 | 61.40±6.47 | 0.002 |
| BMI (kg/m²)              | 24.13±2.94         | 28.07±3.23 | <0.001 |       |       | 22.29±2.83 | 25.96±3.65 | <0.001 |
| SBP (mmHg)               | 131.86±20.01       | 137.22±19.68 | 0.141 |       |       | 136.87±23.30 | 140.16±17.10 | 0.377 |
| DBP (mmHg)               | 76.10±10.94        | 81.11±11.02 | 0.014 |       |       | 75.03±12.41 | 77.91±10.88 | 0.192 |
| FBG (mmol/L)             | 7.69±2.91          | 8.20±2.62 | 0.317 |       |       | 8.53±2.84  | 8.11±2.89  | 0.463 |
| HbA1c (%)                | 8.17±1.60          | 8.36±1.92 | 0.562 |       |       | 8.87±2.17  | 8.69±1.86  | 0.632 |
| Fasting C-peptide (ng/mL)| 0.93 (0.71–1.72)   | 1.55 (1.00–2.09) | 0.010 |       |       | 1.23 (0.64–1.63) | 1.13 (0.71–1.71) | 0.836 |
| HOMA2-IR (units)         | 0.80 (0.56–1.41)   | 1.29 (0.79–1.92) | 0.013 |       |       | 1.02 (0.55–1.50) | 0.99 (0.57–1.46) | 0.945 |
| TG (mmol/L)              | 1.32 (0.98–1.86)   | 1.58 (1.19–2.28) | 0.026 |       |       | 1.46 (0.97–2.12) | 1.40 (1.06–1.95) | 0.941 |
| TC (mmol/L)              | 4.13±0.95          | 4.49±1.01 | 0.050 |       |       | 5.09±1.06  | 4.68±1.01  | 0.044 |
| Creatinine (µmol/L)      | 72.64±17.54        | 74.51±19.63 | 0.590 |       |       | 55.37±15.66 | 56.03±12.88 | 0.803 |
| eGFR (mL/minute/1.73 m²) | 93.84±15.02        | 94.28±15.55 | 0.876 |       |       | 92.53±14.24 | 94.31±12.46 | 0.482 |
| SMI (kg/m²)              | 6.33±0.48          | 7.72±0.58 | <0.001 |       |       | 4.88±0.30  | 6.14±0.65  | <0.001 |
| Body fat percentage (%)  | 27.97±4.61         | 29.14±4.42 | 0.158 |       |       | 35.32±5.11 | 36.04±4.60 | 0.433 |
| Smoking (n, %)           | 20 (39.2%)         | 40 (54.8%) | 0.102 |       |       | 0 (0.0%)  | 0 (0.0%)  | 1.000 |
| AST (U/L)                | 19.06±8.97         | 20.48±8.39 | 0.369 |       |       | 20.84±13.53 | 19.73±7.17 | 0.634 |
| ALT (U/L)                | 19.12±13.20        | 22.51±13.09 | 0.160 |       |       | 16.74±12.33 | 19.72±12.13 | 0.209 |
| TBIL (µmol/L)            | 11.19±4.94         | 12.32±4.69 | 0.199 |       |       | 10.25±4.64 | 9.73±4.13  | 0.530 |
| DBIL (µmol/L)            | 3.86±1.60          | 3.94±1.45 | 0.763 |       |       | 3.56±2.05  | 3.23±1.15  | 0.265 |
| IBIL (µmol/L)            | 7.33±3.48          | 8.37±3.42 | 0.099 |       |       | 6.70±3.14  | 6.49±3.07  | 0.729 |

Continuous data that were normally distributed or non-normally distributed are expressed as the mean± standard deviation (SD) or the median (interquartile range), respectively. Student's t-test (normally distributed data) or Mann–Whitney U-test (non-normally distributed data) were used to compare differences between the two groups. Significant P values (< 0.05) are indicated in bold.

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; HOMA2-IR, homeostasis model assessment of insulin resistance; TG, triglyceride; TC, total cholesterol; eGFR, estimated glomerular filtration rate; SMI, appendicular skeletal muscle mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin.
multiple linear regression analysis to further explore the associations between serum bilirubin concentration and SMI. As shown in Table 2, close relationships of TBIL and IBIL with SMI were only present in men. Furthermore, after adjustment for age, SBP, HbA1c, HOMA2-IR, TG, TC, eGFR, smoking and body fat percentage, TBIL \((p = 0.023)\) and IBIL \((p = 0.012)\) remained significantly associated with SMI in men.

**Multiple logistic regression analysis of the relationships between serum bilirubin and sarcopenia in men and women**

Finally, we conducted multiple logistic regression analyses to explore the
relationships of TBIL and IBIL with sarcopenia, because only TBIL and IBIL were significantly associated with SMI. The male and female participants were allocated to groups according to quartiles of TBIL and IBIL. The highest quartiles of TBIL and IBIL were included in the analysis as independent variables. As shown in Table 3, before adjustment, the highest quartile of IBIL was associated with a low odds ratio (OR) for sarcopenia (OR = 0.380, p = 0.035) in men. After adjustment for age, SBP, HbA1c, HOMA2-IR, TG, TC, eGFR, smoking and body fat percentage, this low OR remained (OR = 0.243, p = 0.009). However, TBIL was not significantly associated with sarcopenia after adjustment in men, and neither TBIL nor IBIL was associated with sarcopenia in women.

**Discussion**

The prevalences of metabolic and musculoskeletal diseases, including T2DM and sarcopenia, increase with age. The bidirectional relationship between T2DM and sarcopenia has been discussed in a previous review. T2DM is characterized by insulin resistance, an inflammatory phenotype, oxidative stress and higher concentrations of advanced glycation end-products (AGEs), which may lead to cell death and further reductions in skeletal muscle mass, strength and function, ultimately resulting in sarcopenia. Bilirubin is one of the most active endogenous antioxidant molecules and has been shown to have beneficial effects in the prevention and treatment of T2DM. However, the role of bilirubin in the pathophysiology of sarcopenia in patients with T2DM has not been explored. To clarify the relationship between serum bilirubin concentration and sarcopenia, we conducted the present cross-sectional study in participants of both sexes.

Unexpectedly, we found that the serum TBIL, DBIL and IBIL concentrations did not significantly differ between participants who did or did not have sarcopenia. The serum bilirubin concentration is lower in smokers and is negatively associated with BMI. As shown in Table 1, male participants with sarcopenia had lower BMIs and were less likely to smoke than those without sarcopenia. In theory, the serum bilirubin concentrations of the sarcopenia group would be expected to be higher than those of the non-sarcopenia group. However, the opposite findings were

| Independent variable | Model 1 | Model 2 |
|----------------------|---------|---------|
|                      | Odds ratio (95% CI) | P   | Odds ratio (95% CI) | P   |
| **Men**              |         |         |                   |       |
| Highest quartile of TBIL | 0.646 (0.273–1.530) | 0.321 | 0.424 (0.153–1.175) | 0.099 |
| Highest quartile of IBIL | 0.380 (0.155–0.933) | **0.035** | 0.243 (0.084–0.703) | **0.009** |
| **Women**            |         |         |                   |       |
| Highest quartile of TBIL | 0.841 (0.348–2.031) | 0.700 | 0.825 (0.297–2.290) | 0.711 |
| Highest quartile of IBIL | 0.891 (0.367–2.159) | 0.798 | 0.829 (0.305–2.254) | 0.714 |

Model 1: unadjusted. Model 2: adjusted for age, SBP, HbA1c, HOMA2-IR, TG, TC, eGFR, smoking, and body fat percentage.

CI, confidence interval; TBIL, total bilirubin; IBIL, indirect bilirubin; SBP, systolic blood pressure; HbA1c, glycated haemoglobin; HOMA2-IR, homeostasis model assessment 2-insulin resistance; TG, triglycerides; TC, total cholesterol; eGFR, estimated glomerular filtration rate.
made, which suggested that the effects of smoke and BMI on serum bilirubin could be modified by the inverse relationship between serum bilirubin and sarcopenia. As shown in Figure 1, we found that TBIL and IBIL positively correlated with SMI in men, but not in women, and the multiple linear regression analysis yielded consistent results. However, in this analysis, only the highest quartile of IBIL was associated with a low OR for sarcopenia after adjustment for multiple factors in men. These data indicate that IBIL, but not DBIL, may play a role in the protection against sarcopenia in men with T2DM.

TBIL is the sum of DBIL and IBIL, and most serum bilirubin is IBIL. Therefore, it is logical that IBIL would play the major role in the protection against sarcopenia, although both IBIL and DBIL have antioxidant properties. Other differences in the clinical significance of DBIL and IBIL have also been identified with respect to other diseases. Patients with Gilbert syndrome who have slightly high IBIL concentrations have lower risks of coronary vascular diseases, whereas this association is not present in patients with Dubin–Johnson syndrome and high DBIL.

A close relationship between serum IBIL and sarcopenia was only identified in men. Several previous studies have shown that men have higher serum bilirubin concentrations than women, and serum bilirubin may also be affected by oestrogen. In addition, sex-specific patterns of aging involve differing changes in muscle mass and quality, as well as in sex hormones. Sex hormones have been shown to be involved in the maintenance of skeletal muscle homeostasis: both testosterone and oestrogen promote muscle protein synthesis, whereas low levels of testosterone and oestrogen are associated with sarcopenia. Moreover, in women, age-associated changes in muscle are mostly reflected in changes in muscle quality, whereas in men they are mostly reflected in a decline in muscle mass. All these differences might influence the sex-specific relationship between bilirubin and sarcopenia.

The present study had some limitations. First, because of the cross-sectional nature of the study, conclusions regarding causal relationships between serum bilirubin concentration and sarcopenia cannot be drawn. Second, the participants in the study were Chinese and aged ≥50 years, and the sample size was relatively small. Therefore, the present findings require confirmation in prospective studies with larger sample sizes and in different age groups. Third, sarcopenia was defined using SMI alone; muscle strength and physical performance were not assessed. Fourth, we did not collect data regarding, or adjust the analyses for the use of medication, despite some anti-diabetic drugs possibly affecting bilirubin concentration and skeletal muscle mass. For example, sodium-glucose co-transporter 2 inhibitors have been shown to increase bilirubin concentration and reduce skeletal muscle mass, and insulin may increase skeletal muscle mass. Finally, some other factors that might influence sarcopenia, such as sex hormones, pro-inflammatory mediators, exercise and smoking history were not fully adjusted for, which might have affected the accuracy of the results.

Conclusions
We have shown that TBIL and IBIL are positively associated with SMI in men with T2DM and that IBIL might be more effective at protecting against the development and progression of sarcopenia. More detailed studies are necessary to further define the interactions between bilirubin and sarcopenia.
Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
The present study was supported by the National Natural Science Foundation of China (No. 81700739).

Author contributions
JBL and CW designed the study and drafted the manuscript. JDL and CJ collected the data. CW and XFY conducted the data analysis. All the authors approved the final version of the manuscript.

ORCID iD
Jidong Liu https://orcid.org/0000-0002-5069-2450

References
1. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 2014; 15: 95–101.
2. Amog K, Raina P, Mayhew AJ, et al. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and meta-analyses. Age Ageing 2018; 48: 48–56.
3. Abellan Van Kan G. Epidemiology and consequences of sarcopenia. J Nutr Health Aging 2009; 13: 708–712.
4. Rolland Y, Czerwinski S, Abellan Van Kan G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008; 12: 433–450.
5. Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271–281.
6. Wang T, Feng X, Zhou J, et al. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Sci Rep 2016; 6: 38937.
7. Kim TN, Park MS, Yang SJ, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 2010; 33: 1497–1499.
8. Park SW, Goodpaster BH, Lee JS, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009; 32: 1993–1997.
9. Yang L, Smith L and Hamer M. Gender-specific risk factors for incident sarcopenia: 8-year follow-up of the English longitudinal study of ageing. J Epidemiol Community Health 2019; 73: 86–88.
10. Mesinovic J, Zengin A, De Courten B, et al. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes 2019; 12: 1057–1072.
11. Inoguchi T, Sonoda N and Maeda Y. Bilirubin as an important physiological modulator of oxidative stress and chronic inflammation in metabolic syndrome and diabetes: a new aspect on old molecule. Diabetol Int 2016; 7: 338–341.
12. Nano J, Muka T, Cepeda M, et al. Association of circulating total bilirubin with the metabolic syndrome and type 2 diabetes: A systematic review and meta-analysis of observational evidence. Diabetes Metab 2016; 42: 389–397.
13. Zhong P, Sun D, Wu D, et al. Total bilirubin is negatively related to diabetes mellitus in Chinese elderly: a community study. Ann Transl Med 2019; 7: 474.
14. Wu Y, Li M, Xu M, et al. Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes 2011; 3: 217–224.
15. Kawamoto R, Ninomiya D and Kumagi T. Handgrip Strength Is Positively Associated with Mildly Elevated Serum Bilirubin Levels among Community-Dwelling Adults. Tohoku J Exp Med 2016; 240: 221–226.
16. Hyun Kim K, Kyung Kim B, Yong Park J, et al. Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. Eur J Gastroenterol Hepatol 2020; 32: 58–65.
17. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: A
report of a WHO/IDF consultation. Geneva: WHO, 2006.

18. Levy JC, Matthews DR and Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. *Diabetes Care* 1998; 21: 2191–2192.

19. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; 150: 604–612.

20. Briggs AM, Woolf AD, Dreihöfer K, et al. Reducing the global burden of musculoskeletal conditions. *Bull World Health Organ* 2018; 96: 366–368.

21. Gazzin S, Vetik L, Watchko J, et al. A Novel Perspective on the Biology of Bilirubin in Health and Disease. *Trends Mol Med* 2016; 22: 758–768.

22. Breimer LH and Mikhailidis DP. Does bilirubin protect against developing diabetes mellitus?. *J Diabetes Complications* 2016; 30: 728–737.

23. Kodal JB, Çolak Y, Kobylecki CJ, et al. Smoking Reduces Plasma Bilirubin: Observational and Genetic Analyses in the Copenhagen General Population Study. *Nicotine Tob Res* 2020; 22: 104–110.

24. Takei R, Inoue T, Sonoda N, et al. Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. *PLoS One* 2019; 14: e0223302.

25. Fevery J. Bilirubin in clinical practice: a review. *Liver Int* 2008; 28: 592–605.

26. Wu TW, Fung KP, Wu J, et al. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. *Biochem Pharmacol* 1996; 51: 859–862.

27. Bulmer AC, Verkade HJ and Wagner KH. Bilirubin and beyond: a review of lipid status in Gilbert’s syndrome and its relevance to cardiovascular disease protection. *Prog Lipid Res* 2013; 52: 193–205.

28. Lee SG, Lee W, Kim JH, et al. Gender-specific reference intervals for serum total bilirubin in healthy Korean adults. *Clin Biochem* 2012; 45: 1257–1259.

29. Walden CE, Knopp RH, Johnson JL, et al. Effect of estrogen/progesterin potency on clinical chemistry measures. The lipid research clinics program prevalence study. *Am J Epidemiol* 1986; 123: 517–531.

30. Di Monaco M, Castiglioni C, Vallero F, et al. Sarcopenia is more prevalent in men than in women after hip fracture: a cross-sectional study of 591 inpatients. *Arch Gerontol Geriatr* 2012; 55: e48–e52.

31. Seo DH, Lee YH, Park SW, et al. Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes. *Diabetes Metab* 2019; 19: 30160.

32. Messier V, Rabasa-Lhoret R, Barbat-Artigas S, et al. Menopause and sarcopenia: A potential role for sex hormones. *Maturitas* 2011; 68: 331–336.

33. Simental-Mendía M, Sánchez-García A, Rodríguez-Ramírez M, et al. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials. *Pharmacol Res* 2021; 163: 105319.

34. Sargeant JA, Henson J, King JA, et al. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. *Endocrinol Metab (Seoul)* 2019; 34: 247–262.